ImmunityBio (NASDAQ:IBRX) Stock Price Up 17.5% – Still a Buy?

ImmunityBio, Inc. (NASDAQ:IBRX)’s stock price traded up 17.5% on Tuesday . The company traded as high as $12.28 and last traded at $11.55. 82,493,534 shares were traded during mid-day trading, an increase of 82% from the average session volume of 45,227,734 shares. The stock had previously closed at $9.83.

Key ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Management reported roughly 700% year‑over‑year revenue growth driven by ANKTIVA commercial sales, a key catalyst lifting investor sentiment and pushing the stock toward its 52‑week high. ImmunityBio Explodes To Near 52-Week High As Bladder Cancer Drug Anktiva Drives Massive 700% Revenue Growth
• Positive Sentiment: The company beat consensus on EPS (loss of $0.06 vs. estimate -$0.08) while reporting ~$38.3M in quarterly revenue, showing improving margins and operational progress versus prior year — a near‑term earnings beat that supports the rally. ImmunityBio Press Release (Q4 Results)
• Positive Sentiment: Regulatory/commercial upside: expanded ANKTIVA approvals in lung cancer and new global commercial partnerships covering ~33 countries, which materially increases addressable market for ANKTIVA sales. ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA Approvals
• Positive Sentiment: An analyst reaffirmation with a high $23 price target (D. Boral Capital) added a buy-side endorsement that likely amplified buying interest. Benzinga – Analyst Coverage
• Neutral Sentiment: Founder Dr. Patrick Soon‑Shiong will present at the Milken Institute / Richard Nixon Foundation “Cancer 2035” summit — a visibility event that can reinforce investor confidence but is informational rather than transactional. ImmunityBio Founder to Speak at Summit
• Neutral Sentiment: Media coverage and chairman comments teasing a multi‑year ANKTIVA expansion plan have driven attention and speculation; useful for sentiment but dependent on execution. MSN – Chairman Teases ANKTIVA Expansion
• Negative Sentiment: Despite the beat, the company remains unprofitable (quarterly GAAP loss reported), and forward EPS estimates remain negative — execution risk and the need to sustain ANKTIVA revenue growth are key risks to the current valuation. ImmunityBio Reports Q4 Loss, Beats Revenue Estimates

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. The Goldman Sachs Group reaffirmed a “buy” rating on shares of ImmunityBio in a research note on Monday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImmunityBio in a research note on Monday, December 29th. Piper Sandler lifted their target price on ImmunityBio from $5.00 to $7.00 and gave the stock an “overweight” rating in a report on Tuesday, January 20th. Jefferies Financial Group boosted their target price on ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Finally, HC Wainwright raised their price target on ImmunityBio from $10.00 to $15.00 and gave the stock a “buy” rating in a research report on Monday. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, ImmunityBio presently has a consensus rating of “Moderate Buy” and an average price target of $12.60.

ImmunityBio Stock Performance

The firm has a market cap of $11.38 billion, a price-to-earnings ratio of -28.17 and a beta of 0.14. The stock has a 50-day moving average of $4.63 and a 200-day moving average of $3.17.

ImmunityBio (NASDAQ:IBRX) last issued its quarterly earnings results on Monday, March 2nd. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.02. The business had revenue of $38.29 million for the quarter. Sell-side analysts predict that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.

Insider Buying and Selling at ImmunityBio

In other ImmunityBio news, Director Christobel Selecky sold 25,000 shares of the business’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $7.51, for a total transaction of $187,750.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Barry J. Simon sold 151,967 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $7.20, for a total value of $1,094,162.40. Following the completion of the transaction, the director owned 3,091,604 shares of the company’s stock, valued at $22,259,548.80. The trade was a 4.69% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 226,967 shares of company stock worth $1,531,912 over the last quarter. Company insiders own 69.48% of the company’s stock.

Institutional Investors Weigh In On ImmunityBio

Large investors have recently made changes to their positions in the stock. Mariner LLC increased its holdings in ImmunityBio by 10.5% during the fourth quarter. Mariner LLC now owns 17,814 shares of the company’s stock worth $35,000 after buying an additional 1,689 shares during the last quarter. Sanctuary Advisors LLC raised its position in shares of ImmunityBio by 6.9% in the fourth quarter. Sanctuary Advisors LLC now owns 29,547 shares of the company’s stock valued at $59,000 after purchasing an additional 1,918 shares during the period. Sequoia Financial Advisors LLC lifted its stake in shares of ImmunityBio by 8.6% during the 4th quarter. Sequoia Financial Advisors LLC now owns 28,783 shares of the company’s stock worth $57,000 after buying an additional 2,271 shares during the last quarter. Mutual Advisors LLC grew its stake in ImmunityBio by 9.0% in the 4th quarter. Mutual Advisors LLC now owns 30,200 shares of the company’s stock valued at $60,000 after buying an additional 2,500 shares during the last quarter. Finally, Commonwealth Equity Services LLC raised its holdings in ImmunityBio by 4.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 75,776 shares of the company’s stock valued at $150,000 after acquiring an additional 3,280 shares during the period. Institutional investors and hedge funds own 8.58% of the company’s stock.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.